Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

SEC Filings

CRDF
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2011Calendar Year 2009Calendar Year 2008Calendar Year 2007Calendar Year 2006Calendar Year 2005Calendar Year 2004Calendar Year 2003
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
UPLOADCorrespondence from the SEC to the FilerNov 30, 2011Open Correspondence from the SEC to the Filer in HTML.Open Correspondence from the SEC to the Filer in DOC file.Open Correspondence from the SEC to the Filer in PDF file.Open Correspondence from the SEC to the Filer in XLS file.
CORRESPCorrespondence from the Filer to the SECNov 25, 2011Open Correspondence from the Filer to the SEC in HTML.Open Correspondence from the Filer to the SEC in DOC file.Open Correspondence from the Filer to the SEC in PDF file.Open Correspondence from the Filer to the SEC in XLS file.